Evidence map›Paper›PMID 37153548›Full record

ArticleFrontiers in immunology2023

Effect of mucosal adjuvant IL-1β on heterotypic immunity in a pig influenza model.

Anna Schmidt, Basudev Paudyal, Sonia Villanueva-Hernández, Adam Mcnee, Eleni Vatzia, Brigid Veronica Carr, Selma Schmidt, Amy Mccarron, Veronica Martini, Silke Schroedel and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Anna SchmidtVirologisches Institut-Klinische und Molekulare Virologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.
Basudev PaudyalHost Responses, The Pirbright Institute, Pirbright, United Kingdom.
Sonia Villanueva-HernándezHost Responses, The Pirbright Institute, Pirbright, United Kingdom.
Adam McneeHost Responses, The Pirbright Institute, Pirbright, United Kingdom.
Eleni VatziaHost Responses, The Pirbright Institute, Pirbright, United Kingdom.
Brigid Veronica CarrHost Responses, The Pirbright Institute, Pirbright, United Kingdom.
Selma SchmidtHost Responses, The Pirbright Institute, Pirbright, United Kingdom.
Amy MccarronHost Responses, The Pirbright Institute, Pirbright, United Kingdom.
Veronica MartiniInstitute for Research in Biomedicine, Bellinzona, Switzerland.
Silke SchroedelSIRION Biotech GmbH, Martinsried, Germany.
Christian ThirionSIRION Biotech GmbH, Martinsried, Germany.
Ryan WatersHost Responses, The Pirbright Institute, Pirbright, United Kingdom.
Francisco J SalgueroUnited Kingdom Health Security Agency, UKHSA-Porton Down, Salisbury, United Kingdom.
Wilhelm GernerHost Responses, The Pirbright Institute, Pirbright, United Kingdom.
Matthias TenbuschVirologisches Institut-Klinische und Molekulare Virologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.
Elma TchilianHost Responses, The Pirbright Institute, Pirbright, United Kingdom.
The Pirbright Institute · GBFriedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversitätsklinikum Erlangen · DE

Funding

Biotechnology and Biological Sciences Research Council BBS/E/I/00007031Biotechnology and Biological Sciences Research Council BBS/E/I/00007039
6 · The paper itself

Abstract

T cell responses directed against highly conserved viral proteins contribute to the clearance of the influenza virus and confer broadly cross-reactive and protective immune responses against a range of influenza viruses in mice and ferrets. We examined the protective efficacy of mucosal delivery of adenoviral vectors expressing hemagglutinin (HA) and nucleoprotein (NP) from the H1N1 virus against heterologous H3N2 challenge in pigs. We also evaluated the effect of mucosal co-delivery of IL-1β, which significantly increased antibody and T cell responses in inbred Babraham pigs. Another group of outbred pigs was first exposed to pH1N1 as an alternative means of inducing heterosubtypic immunity and were subsequently challenged with H3N2. Although both prior infection and adenoviral vector immunization induced strong T-cell responses against the conserved NP protein, none of the treatment groups demonstrated increased protection against the heterologous H3N2 challenge. Ad-HA/NP+Ad-IL-1β immunization increased lung pathology, although viral load was unchanged. These data indicate that heterotypic immunity may be difficult to achieve in pigs and the immunological mechanisms may differ from those in small animal models. Caution should be applied in extrapolating from a single model to humans.

Indexed as

Influenza A Virus, H1N1 SubtypeOrthomyxoviridae InfectionsAdjuvants, ImmunologicAnimalsAntibodies, ViralHumansInfluenza A Virus, H3N2 SubtypeSwineAdjuvants, ImmunologicAntibodies, Viralheterotypic protectionIL-1βinfluenza viruslung-resident memory T-cellsmucosal immunitypigporcine B cellsporcine T-cells

Identifiers

PMID37153548
PMCPMC10159270
OpenAlexW4366590083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.